Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in BBIO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14.2M | $1.06B | -2.4% | 7.254% | 0.02% |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | 13.3M | $984.8M | 0.0% | 6.771% | 18.42% |
| 3 | JANUS HENDERSON GROUP PLC | 13.2M | $978.6M | +19.8% | 6.729% | 0.49% |
| 4 | VIKING GLOBAL INVESTORS LP | 11.8M | $879.4M | -17.7% | 6.046% | 2.46% |
| 5 | FARALLON CAPITAL MANAGEMENT LLC | 9.4M | $695.5M | +4.1% | 4.782% | 4.53% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8.1M | $600.1M | β | 4.126% | 0.03% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 7.8M | $576.2M | β | 3.962% | 0.01% |
| 8 | UBS Group AG | 5.9M | $437.4M | +2.6% | 3.007% | 0.07% |
| 9 | Aisling Capital Management LP | 5.1M | $378.0M | 0.0% | 2.599% | 79.35% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 4.9M | $371.9M | +11.5% | 2.511% | 0.02% |
| 11 | STATE STREET CORP | 4.9M | $366.4M | -0.6% | 2.519% | 0.01% |
| 12 | Invesco Ltd. | 4.6M | $341.1M | -4.9% | 2.345% | 0.05% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 3.6M | $267.9M | -2.8% | 1.842% | 0.03% |
| 14 | Frazier Life Sciences Management, L.P. | 3.4M | $256.1M | -2.8% | 1.760% | 6.59% |
| 15 | CITADEL ADVISORS LLC | 3.4M | $251.8M | +169.7% | 1.731% | 0.12% |
| 16 | TWO SIGMA INVESTMENTS, LP | 3.1M | $231.7M | +60.3% | 1.593% | 0.19% |
| 17 | D. E. Shaw & Co., Inc. | 2.5M | $189.0M | +15.0% | 1.300% | 0.18% |
| 18 | Polar Capital Holdings Plc | 2.5M | $187.1M | +93.9% | 1.286% | 0.66% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 2.5M | $184.5M | +5.8% | 1.268% | 0.03% |
| 20 | FRANKLIN RESOURCES INC | 2.4M | $181.1M | +12.7% | 1.245% | 0.04% |
| 21 | FMR LLC | 2.3M | $174.0M | -1.9% | 1.197% | 0.01% |
| 22 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2.0M | $146.8M | +0.1% | 1.009% | 0.13% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.0M | $146.7M | +0.6% | 1.009% | 0.02% |
| 24 | ALLIANCEBERNSTEIN L.P. | 1.9M | $146.0M | -6.9% | 0.975% | 0.05% |
| 25 | GOLDMAN SACHS GROUP INC | 2.0M | $145.4M | +1.1% | 1.000% | 0.02% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in BBIO β a direct measure of their conviction.
Filings activity in BBIO during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new BBIO position in Q1 2026
Institutions that fully closed their BBIO position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 444 | +5.0% | 109.02% | 2.37 pp | $14.26B | 2.1% |
| Q4 2025 | 423 | +13% | 111.39% | +35.57 pp | $14.57B | +47% |
| Q3 2025 | 376 | +6.8% | 75.82% | +11.07 pp | $9.92B | +17% |
| Q2 2025 | 352 | +21% | 64.75% | +15.57 pp | $8.47B | +32% |
| Q1 2025 | 290 | +16% | 49.18% | +11.56 pp | $6.43B | +31% |
| Q4 2024 | 249 | +3.3% | 37.62% | +4.30 pp | $4.92B | +13% |
| Q3 2024 | 241 | +1.3% | 33.32% | 1.23 pp | $4.36B | 3.6% |
| Q2 2024 | 238 | β | 34.55% | β | $4.52B | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying BBIO stock.
Based on Q1 2026 13F filings, institutional ownership of BridgeBio Pharma, Inc. stands at 109.0%, held across 444 reporting institutions.
BlackRock, Inc. is the largest reported institutional holder of BBIO, with approximately 14,207,757 shares worth $1.06B as of Q1 2026.
Yes β 4 widely-followed marquee investors appear among the top 25 institutional holders of BBIO, including VIKING GLOBAL INVESTORS LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP.
Our composite Smart Money Score for BBIO is 53 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
91 institutions opened new positions in BBIO during Q1 2026, while 70 fully exited. 144 added to existing positions and 205 trimmed.
BBIO institutional ownership fell by 2.37 percentage points quarter-over-quarter, with a net change of +21 holders.
The top 10 institutions account for 48.8% of all reported 13F value in BBIO, and the top 25 account for 71.3%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
BridgeBio Pharma, Inc. (BBIO) Institutional Ownership